Melissa B. Epperly - 01 Jul 2021 Form 4 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)

Reporting relationship: Chief Financial Officer
Issuer ticker: ZNTL
Reported as of: 01 Jul 2021
Net transaction value: -$158,054
SEC form: 4
Accepted by SEC: 06 Jul 2021, 20:01:08 UTC
Prior SEC filing: 14 Jun 2021
Next SEC filing: 20 Aug 2021
Source filing: View source filing
Reporting owner signature: By: /s/ Melissa B. Epperly

Key filing fact

Melissa B. Epperly filed Form 4 for Zentalis Pharmaceuticals, Inc. (ZNTL) on 06 Jul 2021.

Key facts

This page summarizes Melissa B. Epperly's Form 4 filing for Zentalis Pharmaceuticals, Inc. (ZNTL).
4 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 06 Jul 2021, 20:01.

Change

Previous filing in this sequence was filed on 14 Jun 2021.
Current net transaction value: -$158,054.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ZNTL transaction

Common Stock

Sale

Transaction value: $35,073
Shares: -700
Change %: -0.27%
Price: $50.10
Shares after: 259,457
Date: 01 Jul 2021
Ownership: Direct
Footnotes: F1, F2

ZNTL transaction

Common Stock

Sale

Transaction value: $70,479
Shares: -1,378
Change %: -0.53%
Price: $51.15
Shares after: 258,079
Date: 01 Jul 2021
Ownership: Direct
Footnotes: F1, F3

ZNTL transaction

Common Stock

Sale

Transaction value: $41,865
Shares: -805
Change %: -0.31%
Price: $52.01
Shares after: 257,274
Date: 01 Jul 2021
Ownership: Direct
Footnotes: F1, F4

ZNTL transaction

Common Stock

Sale

Transaction value: $10,637
Shares: -200
Change %: -0.08%
Price: $53.18
Shares after: 257,074
Date: 01 Jul 2021
Ownership: Direct
Footnotes: F1, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020.

Footnote F2

The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.68 to $50.58. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F3

The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.71 to $51.57. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F4

The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $51.83 to $52.39. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F5

The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $53.15 to $53.22. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.